drugset / Trial / NCT00743470

A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects

NCT00743470

Phase 1 Terminated 15 enrolled Abbott
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to study the safety, tolerability and pharmacokinetics of rifabutin dosing with lopinavir/ritonavir tablets in healthy volunteers.

Timeline

Start
2008-08
Primary completion
2008-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Rifabutin Small molecule 150 mg
Subject lopinavir/ritonavir Unknown